Constipation during Entecavir treatment in Chronic Hepatitis B patients: Two Cases Reports

The Effect of Entecavir Therapy on Immune Status in Chronic Hepatitis B Patients

Vitiligo Complicating chronic Hepatitis B patients treated with α-Interferon (Report of two cases)

α-Interferon is an antiviral agent used in treatment of chronic hepatitis B. Triggering of the underlying autoimmune disease or exacerbation of pre-existing auto immune disease is documented with α-interferon, but there are few reports about occurrence of autoimmune disorders such as systemic lupus erythematosus, Vitiligo, hypo and hyperthyroidism after administration of α-interferon in the lit...

Association between KIR Genes and Efficacy of Treatment of HBeAg-Positive Chronic Hepatitis B Patients with Entecavir

Background: Entecavir (ETV) is commonly used to treat chronic hepatitis B (CHB) in China. However, certain percentages of e-Antigen (HBeAg) positive CHB patients do not respond to ETV therapy. Objective: To investigate whether the killer immunoglobulin-like receptor (KIR) genes were associated with seroconversion in HBeAg positive CHB responder patients treated with ETV. Methods: Polymerase cha...

Clinical efficacy of tenofovir and entecavir in the treatment of chronic hepatitis B infection in patients naïve to nucleosides and their analogues therapy

Objective: To compare the clinical efficacy and safety of tenofovir and entecavir in chronic hepatitis B patients naïve to nucleosides and their analogues. Methods: A total of 196 patients with chronic hepatitis B, who were naïve to nucleosides and their analogues, were enrolled in this single-blinded controlled study from January 2014 to January 2015. The patients were randomly assigned to ten...

Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B

Early declines in serum hepatitis B surface (HBsAg) levels, their optimal cutoffs, and association with therapeutic endpoints in chronic hepatitis B (CHB) patients receiving entecavir treatment remain unclear. We prospectively enrolled 529 patients (195 hepatitis B e antigen [HBeAg]-positive and 334 HBeAg-negative) with a median treatment duration of 49.2 months. Median HBsAg levels declined si...